Company Filing History:
1 out of 3 
1 out of 832,843 Years Active: 2013-2016
Title: Mark Maginn: Innovator in Antibody Development
Introduction
Mark Maginn is a notable inventor based in Wilburton, GB. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. With a total of 2 patents to his name, his work focuses on enhancing the stability and efficacy of therapeutic antibodies.
Latest Patents
Mark Maginn's latest patents include innovative approaches to anti-nerve growth factor (NGF) antibodies. These antibodies contain an IgG4 constant region with a stabilizing hinge region mutation, which results in an unexpectedly long serum half-life in cynomolgus monkeys. His inventions also encompass pharmaceutical compositions that include the anti-NGF antibodies, nucleic acids encoding these antibodies, and host cells for their expression. Furthermore, he has developed methods for using these antibodies to treat NGF-related diseases or conditions.
Career Highlights
Throughout his career, Mark has worked with prominent organizations, including Abbott Research B.V. His experience in the biotechnology sector has allowed him to contribute to groundbreaking research and development in antibody therapies.
Collaborations
Mark has collaborated with notable professionals in his field, including John Powell and Duncan Casson. These partnerships have further enriched his work and expanded the impact of his inventions.
Conclusion
Mark Maginn is a distinguished inventor whose work in antibody development has the potential to transform treatments for various medical conditions. His innovative patents and collaborations highlight his commitment to advancing biotechnology.